These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35577706)

  • 1. Immunotherapy for Colorectal Cancer.
    Mukherji R; Weinberg BA; Pedersen KS
    Hematol Oncol Clin North Am; 2022 Jun; 36(3):603-626. PubMed ID: 35577706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues.
    Sahin IH; Ciombor KK; Diaz LA; Yu J; Kim R
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-12. PubMed ID: 35658496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer.
    Liang T; Tong W; Ma S; Chang P
    Oncoimmunology; 2020 Jun; 9(1):1773205. PubMed ID: 32934878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
    Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
    Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of metastatic colorectal cancer with synchronous
    Cheng Y; Fang XF; Hu HG; Wang J; Sun LF; Yuan Y
    Immunotherapy; 2020 Mar; 12(4):229-234. PubMed ID: 32172642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors.
    Lengyel CG
    Curr Drug Targets; 2021; 22(9):968-976. PubMed ID: 33970843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
    André T; Cohen R; Salem ME
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective.
    Liu N; Shan F; Ma M
    Int Immunopharmacol; 2021 Oct; 99():108017. PubMed ID: 34352568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic colorectal cancer (Review).
    Choucair K; Radford M; Bansal A; Park R; Saeed A
    Int J Oncol; 2021 Sep; 59(3):. PubMed ID: 34396449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer.
    Bartley AN; Mills AM; Konnick E; Overman M; Ventura CB; Souter L; Colasacco C; Stadler ZK; Kerr S; Howitt BE; Hampel H; Adams SF; Johnson W; Magi-Galluzzi C; Sepulveda AR; Broaddus RR
    Arch Pathol Lab Med; 2022 Oct; 146(10):1194-1210. PubMed ID: 35920830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy regimens for metastatic colorectal carcinomas.
    Bashir B; Snook AE
    Hum Vaccin Immunother; 2018 Feb; 14(2):250-254. PubMed ID: 29083978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
    Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
    Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
    Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T
    Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients.
    Wang D; Zhang H; Xiang T; Wang G
    Front Immunol; 2021; 12():762341. PubMed ID: 34721435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
    Tan E; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
    [No Abstract]   [Full Text] [Related]  

  • 20. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
    Lee V; Murphy A; Le DT; Diaz LA
    Oncologist; 2016 Oct; 21(10):1200-1211. PubMed ID: 27412392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.